Some clouds and possibly an isolated thunderstorm this afternoon. A few storms may be severe. High 83F. Winds WSW at 10 to 15 mph. Chance of rain 30%..
Tonight
Partly cloudy skies. Low 62F. Winds NW at 5 to 10 mph.
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended June 30, 2026 (the "Reporting Period").
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 15, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, and Kelun-Biotech (6990.HK) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7575/SKB575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-developed by the two parties, Â for the treatment of asthma. Previously, the first participant has been dosed in a Phase 1 clinical study of HBM7575/SKB575 for the treatment of atopic dermatitis.
